Allosteric Inhibition of Hypoxia Inducible Factor-2 with Small Molecules

Hypoxia Inducible Factors (HIFs) are heterodimeric transcription factors induced in many cancers where they frequently promote the expression of many protumorigenic pathways. Though transcription factors are typically considered “undruggable”, the PAS-B domain of the HIF-2α subunit contains a large cavity within its hydrophobic core that offers a unique foothold for small-molecule regulation. Here we identify artificial ligands that bind within this pocket and characterize the resulting structural and functional changes caused by binding. Notably, these ligands antagonize HIF-2 heterodimerization and DNA-binding activity in vitro and in cultured cells, reducing HIF-2 target gene expression. Despite the high identity between HIF-2α and HIF-1α, these ligands are highly selective and do not affect HIF-1 function. These chemical tools establish the molecular basis for selective regulation of HIF-2, providing potential therapeutic opportunities to intervene in HIF-2-driven tumors such as renal cell carcinomas.

[1]  W. Kaelin.  Treatment of kidney cancer , 2009, Cancer.

[2]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[3]  Kentaro Takahashi,et al.  Von Hippel-Lindau Disease , 2024 .

[4]  M. Ohh,et al.  The updated biology of hypoxia‐inducible factor , 2012, The EMBO journal.

[5]  Jared Rutter,et al.  Structure and interactions of PAS kinase N-terminal PAS domain: model for intramolecular kinase regulation. , 2002, Structure.

[6]  G. Semenza.  HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.

[7]  Å. Borg,et al.  Recruitment of HIF-1 a and HIF-2 a to common target genes is differentially regulated in neuroblastoma : HIF-2 a promotes an aggressive phenotype , 2022 .

[8]  Kojima.  Structure and function , 2005 .

[9]  James V Belcastro,et al.  An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. , 2008, Assay and drug development technologies.

[10]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[11]  W. Kaelin,et al.  Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.

[12]  Keith Moffat,et al.  N- and C-terminal flanking regions modulate light-induced signal transduction in the LOV2 domain of the blue light sensor phototropin 1 from Avena sativa. , 2007, Biochemistry.

[13]  Brian Keith,et al.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression , 2011, Nature Reviews Cancer.

[14]  A. Sali,et al.  Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.

[15]  Lei Zhang,et al.  Functions of the Per/ARNT/Sim Domains of the Hypoxia-inducible Factor* , 2005, Journal of Biological Chemistry.

[16]  C. Holterman,et al.  Human cancers converge at the HIF-2α oncogenic axis , 2009, Proceedings of the National Academy of Sciences.

[17]  K. Gardner,et al.  Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B , 2011, Proceedings of the National Academy of Sciences.

[18]  D. Peet,et al.  Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch , 2002, Science.

[19]  R. Chen,et al.  Regulation of Hypoxia-Inducible Factor 2α Signaling by the Stress-Responsive Deacetylase Sirtuin 1 , 2009, Science.

[20]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[21]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[22]  G. Qing,et al.  Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. , 2009, Current opinion in genetics & development.

[23]  D. Gisselsson,et al.  HIF-2α maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells , 2009, Proceedings of the National Academy of Sciences.

[24]  J. Richardson,et al.  HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. , 2005, Blood.

[25]  Kevin H. Gardner,et al.  Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor , 2009, Proceedings of the National Academy of Sciences.

[26]  James V Belcastro,et al.  An automated high throughput liquid chromatography-mass spectrometry process to assess the metabolic stability of drug candidates. , 2007, Assay and drug development technologies.

[27]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[28]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[29]  Jiannis Ragoussis,et al.  High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. , 2011, Blood.

[30]  雅州 坂口,et al.  [Von Hippel-Lindau disease]. , 2012 .

[31]  W. Wong,et al.  Hypoxia-inducible factors and the response to hypoxic stress. , 2010, Molecular cell.

[32]  Thomas H Scheuermann,et al.  Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor. , 2013, Journal of medicinal chemistry.

[33]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[34]  Wei Li,et al.  Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis , 2009, Proceedings of the National Academy of Sciences.

[35]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[36]  G. Semenza.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. , 2012, Trends in pharmacological sciences.

[37]  Kevin H. Gardner,et al.  Structural Basis of a Phototropin Light Switch , 2003, Science.

[38]  K. Gardner,et al.  Molecular Basis of Coiled Coil Coactivator Recruitment by the Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT)* , 2009, Journal of Biological Chemistry.

[39]  C. Peterson,et al.  Chromatin immunoprecipitation (ChIP). , 2009, Cold Spring Harbor protocols.

[40]  L. Chodosh,et al.  HIF-2α deletion promotes Kras-driven lung tumor development , 2010, Proceedings of the National Academy of Sciences.

[41]  R. Chen,et al.  Hypoxia Increases Sirtuin 1 Expression in a Hypoxia-inducible Factor-dependent Manner* , 2011, The Journal of Biological Chemistry.

[42]  Angela N Koehler,et al.  A complex task? Direct modulation of transcription factors with small molecules. , 2010, Current opinion in chemical biology.

[43]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[44]  Randy J. Read,et al.  Phenix - a comprehensive python-based system for macromolecular structure solution , 2012 .

[45]  S. Crosson,et al.  Ligand-binding PAS domains in a genomic, cellular, and structural context. , 2011, Annual review of microbiology.

[46]  Huafeng Zhang,et al.  Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization , 2009, Proceedings of the National Academy of Sciences.

[47]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[48]  Valerie Daggett,et al.  Principles of ligand binding within a completely buried cavity in HIF2alpha PAS-B. , 2009, Journal of the American Chemical Society.

[49]  D. Peet,et al.  FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. , 2002, Genes & development.

[50]  Till Acker,et al.  Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function , 2000, Oncogene.

[51]  Rameen Beroukhim,et al.  Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. , 2011, Cancer discovery.

[52]  K. Gardner,et al.  Structural basis for PAS domain heterodimerization in the basic helix–loop–helix-PAS transcription factor hypoxia-inducible factor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Shoemaker,et al.  Targeting the PAS-A Domain of HIF-1α for Development of Small Molecule Inhibitors of HIF-1 , 2006, Cell cycle.

[54]  K. Gardner,et al.  Hypoxia-inducible factors Per/ARNT/Sim domains: structure and function. , 2007, Methods in Enzymology.

[55]  Å. Borg,et al.  Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. , 2006, Cancer cell.

[56]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[57]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[58]  A. Bookout,et al.  Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways , 2003, Nuclear receptor signaling.

[59]  H. Kowarzyk.  Structure and Function. , 1910, Nature.

[60]  Jan Lubinski,et al.  Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. , 2009, Anticancer research.

[61]  Bruce A. Johnson,et al.  NMR View: A computer program for the visualization and analysis of NMR data , 1994, Journal of biomolecular NMR.